Navigation Links
Generation of a severe memory-deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha
Date:6/19/2009

Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is an enzyme that adds phosphates to a variety of protein substrates to modify their functions. CaMKII alpha is enriched in the hippocampus, the memory center of the brain, and is believed to be an essential mediator of activity-dependent synaptic plasticity and memory functions. However, the causative role of the enzymatic activity of CaMKII alpha in such processes has not been demonstrated yet, because this enzyme has multiple protein functions other than the kinase activity. A Japanese research group, led by Dr Yoko Yamagata of the National Institute for Physiological Sciences, Japan, has successfully generated a novel kinase-dead mutant mouse of the CaMKII alpha gene that completely and exclusively lacks its kinase activity. They examined hippocampal synaptic plasticity and behavioral learning of the mouse, and found a severe deficit in both processes. They reported their findings in the Journal of Neuroscience, published on June 10, 2009.

The research group successfully generated a novel CaMKII alpha (K42R) knock-in mouse that completely lacks the kinase activity of CaMKII alpha, and examined the effects on structural, functional, and behavioral expression of synaptic memory. In the K42R brain, tetanus-induced long-term potentiation (LTP), a proposed cellular mechanism of memory, and sustained postsynaptic spine enlargement, a structural basis for LTP, were both impaired, whereas dynamic postsynaptic movement of CaMKII alpha protein was preserved. In addition, the K42R mouse showed a severe deficit in inhibitory avoidance learning, a form of memory dependent on the hippocampus. The research group concluded that the mutant mouse could not form memories and did not remember the events that had just happened.

"We demonstrated that the mutant mouse has a severe memory deficit because of the lack of the kinase activity of CaMKII alpha. This finding supports the idea that the kinase activity of CaMKII alpha is essential to memory functions. Such a memory-deficit mutant mouse could serve as an animal model to study the molecular mechanisms of memory, and be a useful tool for the development and screening of therapeutic reagents for memory-deficit disorders. It may also help open a new therapeutic approach to memory dysfunctions in patients.", said Dr Yamagata.


'/>"/>

Contact: Dr. Yoko Yamagata
yamagata@nips.ac.jp
81-564-595-887
National Institute for Physiological Sciences
Source:Eurekalert

Related medicine news :

1. Next Generation Waters - Nuu
2. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
3. Abbott Announces Launch of Next-Generation Embolic Protection System
4. Purity Products Partners with Leading Vitamin D Expert to Create Next-Generation D3 Complex
5. San Francisco Symposium Provides Training for Communities Looking to Develop Arts Programs That Unite Generations
6. RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment
7. Nonin Medical Introduces Next-Generation Regional Oximeter at Euroanaesthesia 2009
8. ZigBee Selected by Continua Health Alliance for Next Generation Guidelines
9. Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution
10. First heart patients implanted with next-generation mechanical heart pump
11. AARP to Host Cross-Generational Life Festival in Chicago, June 5-6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, ... steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, a ... the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of ... Sadati, is pleased to announce a new treatment option called Vivace Microneedling. This ... face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, ... experienced dentist practicing in Mt. Pleasant, SC, with or without a referral. A full ... patients with missing teeth in Charleston, SC. Those who suffer from gum ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: